about
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumoursIssues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs.Update on tubulin-binding agents.First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.How many diseases are colorectal cancer?Spindle cell carcinoma of the head and neck region: treatment and outcomes of 15 patientsBiomarker method validation in anticancer drug developmentDevelopment of a circulating miRNA assay to monitor tumor burden: From mouse to manThe interaction between prognostic and pharmacodynamic biomarkers.Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapyA study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity.Biomarkers of cell death applicable to early clinical trials.Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.The use of circulating biomarkers in early clinical trials in patients with cancer.Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line settingMetastatic Brain Disease from Non-small Cell Lung Cancer - Getting Back to the Drawing Board.Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer.Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.Assessment of diurnal changes and confounding factors that affect circulating cell death biomarker levels: a short communication.A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.Learning from toxicity patterns in phase I trials during the era of mechanism targeted agents.A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursA Pilot Study Assessing the Prognostic Value of CK18 and nDNA Biomarkers in Severe Sepsis PatientsClinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung CancerEvaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung CancerIsolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung CancerSerum biomarkers of apoptosisTransfer and Metabolism of Prostaglandin E2in the Dual Perfused Human PlacentaAn introduction to stratified medicine
P50
Q33394173-D8025980-7224-477A-A424-AF50BA89DB8DQ33847836-A6827218-F83C-41D2-846D-02909B95DD70Q34503114-138E46F2-70DA-44B1-9CAF-40598C549ADBQ35881827-D198F905-CD3D-435A-A5F9-EDEB01BB431DQ36238965-798DC456-A224-41D9-9A84-5C1DDEE666F8Q36319411-3DF58634-927B-4253-944D-DA0CA3B92F01Q36484621-A0C2694F-0D35-4F9E-A813-BCC29DE4F463Q36571424-D927E486-93F6-43C3-80F2-1383D7043660Q37214321-83934288-2567-45B2-9C33-428AF1596056Q37278502-F6845E25-FBFD-499F-88D6-336712B8E808Q37322979-118E4F0E-4660-4A26-8BDD-07EC82897617Q38000847-2C68C821-5A50-479B-8A9C-45A39832980FQ38418038-D6F8031F-C8C4-494D-943E-344B22473517Q38600479-D6A9F7D9-441C-458B-92B4-D2EBCE56FD03Q38609692-DE5AC9B0-9C85-4DEC-9717-83FC67159CAAQ39152521-AE5526EB-4ACD-442F-BA83-71E40305175CQ42275107-B4FDF5F6-112D-4C0B-84B9-A8F02AA29C8CQ47850620-C86F3086-0D3C-4553-9356-081212DF38BAQ48001140-B8667260-7794-46BD-97D3-3F6F894A4463Q48022028-FD49A6F8-8D8B-41E2-A78A-36789B7CF25AQ49602341-0AD2195B-0327-4686-B783-A6E2B388A750Q50849269-47A6A3B7-F1E4-4A0E-A305-F902D331D400Q51441307-86E69E24-9DA0-4B7F-9215-622B9CBD9DFFQ51732261-5723EF6A-2329-4951-83A9-30436ED319EFQ51792902-08E4353C-1C2A-4C3C-A38B-714AF14022A6Q53131141-0A4B2172-D359-4544-9757-3C3F1DFEDC78Q54317902-AAA04E32-1FE1-46E6-AE20-BDB2ADC9909EQ57694020-DC3FDE7A-551E-47EC-A281-8791FB6ADA60Q58282319-74E9F92C-F268-4130-B4F2-B307CB2AE3C7Q58282332-8BE0302A-5392-4AD9-BAC0-7B31369C8D17Q58282415-13950C74-E014-4FE8-BF0C-7307946D069EQ58282635-A30E00F0-B4A2-4FFC-9D7D-2179CDC5086EQ59305033-470A62D7-F15F-4DB4-B296-812FE264C3BFQ64449002-99D10D58-593A-40F4-A14E-752DAE20D717Q85856152-5F436B07-F6EF-4B52-B000-6D80DE76F946
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Alastair Peter Greystoke
@ast
Alastair Peter Greystoke
@en
Alastair Peter Greystoke
@es
Alastair Peter Greystoke
@nl
Alastair Peter Greystoke
@sl
type
label
Alastair Peter Greystoke
@ast
Alastair Peter Greystoke
@en
Alastair Peter Greystoke
@es
Alastair Peter Greystoke
@nl
Alastair Peter Greystoke
@sl
prefLabel
Alastair Peter Greystoke
@ast
Alastair Peter Greystoke
@en
Alastair Peter Greystoke
@es
Alastair Peter Greystoke
@nl
Alastair Peter Greystoke
@sl
P106
P1153
22940493900
P21
P31
P496
0000-0001-9168-0387